advanced search

Evonik

Evonik Health Care is a CDMO for advanced oral and parenteral drug delivery solutions covering early development to commercial manufacturing. Evonik Health Care is also one of the world’s largest CMOs for APIs, intermediates, amino acids, cell culture ingredients and medical device excipients.


Visit Website

Headquarters
Evonik Industries AG
Rellinghauser Straße 1-11
45128, Essen
Germany

Phone / Contact

T: +49 201 177 01
F: +49 201 177 3475
E: [email protected]

Connect

Evonik Health Care is a CDMO for advanced oral and parenteral drug delivery solutions, which supports customers along the whole value chain from early development to commercial manufacturing. Evonik Health Care is also one of the world’s largest CMOs for active pharmaceutical ingredients (APIs) and intermediates, as well as a supplier of amino acids, cell culture ingredients and medical device excipients.

Articles by Evonik

GI/ORAL
Dr Bettina Hölzer
PRODUCT SHOWCASE: Optimising Gastric Resistance in Complex Oral Drug Products with Novel, Functional, Ready-To-Fill Capsules
Evonik showcases its novel, functional, ready-to-fill capsules portfolio, EUDRACAP®, explaining how its role in optimising gastric resistance in complex oral drug products.
GI/ORAL
Dr Jessica Mueller-Albers
The Secrets of Solubility Enhancement Success with EUDRAGIT® Carriers
Jessica Mueller-Albers discusses how Evonik’s EUDRAGIT® functional polymers can enhance drug solubility and permeability, with a focus on carriers, screening tools and manufacturing processes.
GI/ORAL
PRODUCT SHOWCASE: Evonik’s newly launched EUDRACAP™ functional, ready-to-fill capsules
Evonik introduces EUDRACAP™, its newly launched platform of functional ready-to-fill HPMC capsules, which helps optimise release profile, protects sensitive active ingredients, and speeds time to market.
INDUSTRIALISATION
Stephen Allan
FROM FORMULATION TO MANUFACTURING: LIPID NANOPARTICLE mRNA VACCINES, GENE THERAPIES & OTHER NANOMEDICINES
Stephen Allan reviews the history and formulation advantages of lipid nanoparticles (LNPs) and addresses factors that should be considered by pharmaceutical companies during the CDMO selection process to help reduce regulatory risk, improve product performance and accelerate speed to market.
GI/ORAL
Dr Maria Montero Mirabet
ADVANCED APPROACHES FOR DELAYED-RELEASE FORMULATIONS
Maria Montero Mirabet and Brigitte Skalsky, both of Evonik Health Care, review advances in delayed-release technology including advances in enteric-coating applications and the use of pulsatile technology to provide tailored lag times.
GI/ORAL
Hans Baer
AN INNOVATIVE SMART ORAL DELIVERY TECHNOLOGY FOR PROTEINS AND PEPTIDES
Andrea Engel, Anne Benedikt and Hans Baer explain how their recently introduced new modular platform technology for improving the oral bioavailability of peptides may offer a feasible solution to the problem of compliance with peptide drugs.
Top